echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > On January 7th, CDE issued 5 more clinically relevant guidelines, involving innovative drugs, improved new drugs, and traditional Chinese medicines. A total of nearly 20 were released this week!

    On January 7th, CDE issued 5 more clinically relevant guidelines, involving innovative drugs, improved new drugs, and traditional Chinese medicines. A total of nearly 20 were released this week!

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Introduction: Today, CDE has issued 5 more guiding principles, including innovative drugs , improved new drugs , new traditional Chinese medicine drugs , and clinical and non-clinical related information.
    See below for details

    .

    Introduction: innovative drugs, improved new drugs, traditional Chinese medicine , clinical non-clinical drugs

    "Guidelines for random allocation of drug clinical trials (trial)", "Technical principles for human bioavailability and bioequivalence research of innovative drugs", "Technical principles for clinical pharmacokinetics research of modified-release modified new drugs", "Non-clinical drugs" Technical Guiding Principles for Dependence Research, "Technical Guiding Principles for Studying Samples for Toxicology Research of New Chinese Medicines (Trial)"

    In order to clarify the relevant technical requirements for the design and implementation of random allocation in clinical trial research, the Center for Drug Evaluation organized the formulation of the "Guidelines for Random Allocation of Drug Clinical Trials (Trial)" (see attachment)
    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .

    hereby notified
    .

    Annex: Guidelines for random allocation of drug clinical trials (trial)

    Drug Evaluation Center of the State Food and Drug Administration

    January 4, 2022

    In order to further encourage and guide the scientific and rational development of human bioavailability and bioequivalence research during the clinical trials of innovative drugs and after they are put on the market, under the deployment of the State Drug Administration, the Center for Drug Evaluation organized and formulated the "Innovative Drug Human Technical Guidelines for Bioavailability and Bioequivalence Studies (see annex)
    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guidance Principles for Drugs" (Medical Administration Comprehensive Drug Administration [2020] No.
    9), it is hereby issued with the approval of the State Food and Drug Administration

    .

    hereby notified
    .

    Annex: Technical Guidelines for Human Bioavailability and Bioequivalence Research of Innovative Drugs

    Drug Evaluation Center of the State Food and Drug Administration

    January 4, 2022

    In order to further encourage and guide the reasonable and standardized pharmacokinetic research of modified-release preparations in improved new drugs and provide technical specifications for reference, the Center for Drug Evaluation organized the formulation of the "Technical Guidance for Clinical Pharmacokinetics Research of Modified-Release Preparations of Improved New Drugs".
    Principles (see appendix)

    .

    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .

    hereby notified
    .

    Attachment: Technical Guiding Principles for Clinical Pharmacokinetic Research of Modified Release Preparations of Modified New Drugs

    Drug Evaluation Center of the State Food and Drug Administration

    January 4, 2022

    In order to guide and standardize drug non-clinical dependence research, under the deployment of the State Drug Administration, the Center for Drug Evaluation organized the revision of the "Technical Guiding Principles of Drug Non-clinical Dependence Research"
    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .
    The "Technical Guiding Principles for Drug Non-clinical Dependence Research" issued by the former State Food and Drug Administration in 2007 is abolished

    .

    hereby notified
    .

    Annex: Technical Guidelines for Drug Nonclinical Dependence Research

    Drug Evaluation Center of the State Food and Drug Administration

    January 4, 2022

    Under the deployment of the State Drug Administration, the Center for Drug Evaluation organized the formulation of the "Technical Guidelines for the Study of Samples for Toxicology Research of New Chinese Medicines (for Trial Implementation)" (see attachment)
    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .

    hereby notified
    .

    Appendix:

    1.
    Technical Guiding Principles of Sample Research for Toxicology Research of New Chinese Medicines (Trial)

    2.
    Drafting instructions for "Technical Guidelines for Research on Samples for Toxicology Research of New Chinese Medicines (Trial)"

    Drug Evaluation Center of the State Food and Drug Administration

    January 4, 2022

    A total of 19 guiding principles/comments/notifications were issued this week, 14 have been issued before, see below
    .

    A total of 19 guiding principles/comments/notifications were issued this week, 14 have been issued before, see below
    .

    "Technical Guidelines for Clinical Research and Development of Rare Disease Drugs"

    Guidelines for Clinical Trial Design of Drugs for the Prevention of Nausea and Vomiting Caused by Antineoplastic Drugs (Trial)

    "Technical Guidelines for Pharmacokinetic Research in Patients with Renal Insufficiency (Trial)"

    "Guidelines for Writing a Clinical Risk Management Plan (Trial)"

    Publicly solicit opinions on the "Guidelines for Communication and Communication Technology Based on the "Three Combinations" Registration Review Evidence System

    Notice on the application of E2B (R3) regional implementation guidelines for individual safety reports during drug clinical trials

    "Technical guidelines for clinical trials of direct-acting antiviral drugs in chronic viral hepatitis C"

    "Technical Guidelines for Clinical Trials of Ulcerative Colitis Drugs"

    "Technical Guidelines for Clinical Trials of Drugs for the Treatment of Crohn's Disease"

    "Technical Guidelines for Food Impact Research in New Drug Development"

    Guidelines for Data Management and Statistical Analysis Plans for Drug Clinical Trials

    "Guiding Principles for the Application of Patient-Reported Outcomes in Drug Clinical Development (Trial)"

    "Technical Guiding Principles for Crystal Form Research of Chemical Generic Drugs (Trial)"

    "Technical Guidelines for Writing Safety Reference Information in the Investigator's Handbook"

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.